Melatonin for Prevention of Post- Operative Delirium Pilot Study Protocol

NCT ID: NCT02903901

Last Updated: 2016-09-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-30

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To test the efficacy of melatonin compared to placebo in preventing post-operative delirium and reduction in intensity or duration of delirium in individuals 65 years of age and older who undergo orthopedic surgery after low energy lower extremity fractures (LELEF).

Biomarkers may play important roles in the detection, prediction and management of delirium especially in frail elderly individuals. Predictive biomarkers may help characterize an individual's susceptibility to delirium and thereby help specialized treatment, care and management of such individuals during their hospitalization. They may also help predict treatment response to a specific modality and help in selection of such modality. Recent studies performed in the UK and published in 2011 have measured plasma cholinesterase activity and determined that these levels were lower in patients who developed delirium compared with remaining subjects. Other studies have indicated that CRP may also have a role in delirium prediction as they have found that CRP measured on admission to an ICU had predictable changes that occurred within 24 hours that in turn were predictors of delirium. One the aims of the study is to compare the predictive and treatment response values of groups of biomarkers that have been hypothesized to be of predictive value.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Surgery causes oxidative stress on the brain9 leading to inflammation. Post-operative delirium has been linked with inflammation in the brain. Delirium has been hypothesized to be a central nervous system response to systemic inflammation during a state of blood-brain barrier (BBB) compromise.

Studies have shown a rise of inflammatory cytokines and fall of anti-inflammatory cytokines. Vice-versa, external cytokine administration has been shown to lead to delirium. Melatonin is known for its strong anti-oxidant and anti-inflammatory properties, this should account for its preventive properties in post-operative delirium. It has also been hypothesized that post-operative delirium in elderly is caused by circadian rhythm disturbances secondary to a relative lack of melatonin.

Keeping in mind the above two possible pathophysiology for delirium, investigators are expecting melatonin supplementation should be able to reduce the incidence of post-operative delirium particularly in elderly population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Delirium

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Individuals who are randomized to the control arm will receive liquid placebo sublingually 60-90 minutes prior to surgery.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

10 mg liquid placebo at 7 pm for 1 week

Melatonin

Individuals who are randomized to the treatment arm will receive 10 mg liquid IR-SL melatonin 60-90 minutes prior to surgery

Group Type ACTIVE_COMPARATOR

Melatonin

Intervention Type DRUG

10 mg liquid Melatonin IR-SL at 7 pm for 1 week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Melatonin

10 mg liquid Melatonin IR-SL at 7 pm for 1 week

Intervention Type DRUG

Placebo

10 mg liquid placebo at 7 pm for 1 week

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 65 years of age and older undergoing Low Energy Lower Extremity Fractures (LELEF) surgery
* Presence of an LELEF fracture
* Low Energy (e.g., falls from standing height, falls from sitting, etc.).
* Operative Fractures:

* Pathologic femur and tibia fractures
* Femoral neck fractures
* Pertroch: including intertroch, subtroch fractures
* Femoral shaft
* Supracondylar femur fractures
* Periprosthetic fractures around total hip and total knee arthroplasties
* Tibial plateau fractures
* Proximal Tibia Fractures
* Tibial Shaft Fractures
* Distal 1/3 tibia fractures
* Ankle Fractures that are admitted

Exclusion Criteria

* Patients with previous adverse reaction or side-effects to melatonin
* Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
* Inability to communicate in English
* Patients with a Montreal Cognitive Assessment (MoCA) score of below 7 will not be included in the study because of their inability to give informed consent at that stage. This score is approximately 2 standard deviation below average score for Alzheimer's Dementia.
* Participants who are unable to give consent or communicate well in English will not be enrolled
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Loyola University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Muralidhara Rao

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Muralidhara S Rao, MD

Role: PRINCIPAL_INVESTIGATOR

Loyola University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Loyola University Medical Center

Maywood, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Deiner S, Silverstein JH. Postoperative delirium and cognitive dysfunction. Br J Anaesth. 2009 Dec;103 Suppl 1(Suppl 1):i41-46. doi: 10.1093/bja/aep291.

Reference Type BACKGROUND
PMID: 20007989 (View on PubMed)

Bekker AY, Weeks EJ. Cognitive function after anaesthesia in the elderly. Best Pract Res Clin Anaesthesiol. 2003 Jun;17(2):259-72. doi: 10.1016/s1521-6896(03)00005-3.

Reference Type BACKGROUND
PMID: 12817919 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

206981

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Namenda to Prevent Post-Operative Delirium
NCT00303433 TERMINATED PHASE4